Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bifidobacterium breve capable of relieving Alzheimer's disease and increasing fecal acetic acid content and application thereof

A technology of Bifidobacterium breve and bacterial agent, applied in the field of microorganisms, can solve the problems of complex research methods of intestinal flora, lack of types of psychoactive probiotics, and few clinical studies of intestinal flora, etc., and improve the degree of species diversity. , improve the relative abundance, improve the effect of cognitive impairment

Active Publication Date: 2021-08-06
JIANGNAN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the types of "mental probiotics" that are known to be used to prevent and treat neurological diseases are too scarce; secondly, due to the complexity of the intestinal flora and the difficulty of research methods, there are few clinical studies on the intestinal flora, and their participation The mechanism of body metabolism and interaction has not been clarified; therefore, it is very important to screen out a probiotic that can mediate intestinal flora to relieve Alzheimer's disease, dig into its function, and develop probiotic products with higher health value. important

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bifidobacterium breve capable of relieving Alzheimer's disease and increasing fecal acetic acid content and application thereof
  • Bifidobacterium breve capable of relieving Alzheimer's disease and increasing fecal acetic acid content and application thereof
  • Bifidobacterium breve capable of relieving Alzheimer's disease and increasing fecal acetic acid content and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Screening and Identification of Example 1 Bifidobacterium breve CCFM1179

[0050] (1) Isolation and screening of bacterial strains:

[0051] (1) Use a disposable aseptic toilet to collect the feces of a 10-month-old male infant who is exclusively breastfed in Wuxi City, Jiangsu Province, and the feces samples are contained in the MRS+ mass percentage (0.05%-0.1%) of fructooligosaccharides. Cysteine ​​medium, in an anaerobic incubator (N 2 :CO 2 :H 2 =80:10:10) enriched for 12h;

[0052] (2) The feces samples were serially diluted with sterile saline, and then spread on the MRS+ mass percentage (0.05%-0.1%) L- On the solid plate of cysteine ​​hydrochloride, cultivate for 24-48h;

[0053] (3) Select a single colony conforming to the basic form of bifidobacteria to carry out streaking and purification on the plate, and screen and isolate the selected bacterial strain;

[0054] (4) The above-mentioned single colonies were cultured in liquid MRS+mass percentage (0.05%-...

Embodiment 2

[0076] Example 2 Bifidobacterium breve CCFM1179 improves the behavioral indicators of Alzheimer's disease mice

[0077] Thirty-two 7-week-old male C57BL / 6J mice were taken, and after one week of adaptation to the environment, the animal model of Alzheimer's disease was established by one-time microinjection of Aβ1-42 protein into the hippocampus of the brain. Divided into four groups: control group (injection of equal volume of normal saline), model group, drug intervention group, CCFM1179 intervention group, each group contains 8 mice. The animal groups and treatment methods are shown in Table 1.

[0078] Table 1 Grouping and processing methods of animal experiments

[0079]

[0080]AD mouse model induced by microinjection of Aβ1-42 protein in the brain: After the mice were adapted for one week, the mice in each group were anesthetized with isoflurane (induction concentration 3%, maintenance concentration 1%), and the hair on the top of the mice was removed. After disinf...

Embodiment 3

[0093] Example 3 CCFM1179 reduces Aβ protein deposition in the brain of Alzheimer's disease mice

[0094] The mouse grouping, modeling and treatment methods are the same as in Example 2. After the mouse behavior experiment, the next day, the mice were injected intraperitoneally with 1% pentobarbital sodium solution to make them anesthetized, and the mice were killed. The brain tissue of the mice was taken and separated on ice. Hippocampus. Take a certain quality of fresh hippocampus tissue, add 9 times the volume of sterile PBS buffer solution (equivalent to 1g tissue plus 9ml homogenate), homogenize with a tissue homogenizer, and take the supernatant after the tissue fluid is centrifuged at 3000g for 15min. The content of Aβ1-42 in the hippocampus was detected by ELISA kit.

[0095] Experimental results such as figure 2 As shown, the results show that the intervention of Bifidobacterium breve CCFM1179 can significantly reduce the deposition of Aβ1-42 protein in the hippoc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Bacteriaaaaaaaaaaa
Bacteriaaaaaaaaaaa
Login to View More

Abstract

The invention discloses bifidobacterium breve capable of relieving Alzheimer's disease and increasing fecal acetic acid content and application thereof, and belongs to the field of microorganisms. The bifidobacterium breve CCFM1179 can significantly improve cognitive and memory disorders of mice with Alzheimer's disease, reduce the content of A beta 1-42 in the brains of the mice with Alzheimer's disease, increase the level of brain-derived neurotrophic factors and postsynaptic density protein in the brains of the mice with Alzheimer's disease, increase the content of 5-hydroxytryptamine in the serum of the mice with Alzheimer's disease, and regulate intestinal flora and metabolites thereof. The bifidobacterium breve CCFM1179 can be used for preparing pharmaceutical compositions for relieving dementia and Alzheimer's disease and improving cognitive disorders, can also be used as a microecological preparation to be applied to drugs, fermented food or health care products, and has a very wide application prospect.

Description

technical field [0001] The invention relates to a strain of bifidobacterium breve capable of alleviating Alzheimer's disease and increasing feces acetic acid content and application thereof, belonging to the field of microorganisms. Background technique [0002] Alzheimer's disease, also known as senile dementia, is a neurodegenerative disease, clinically manifested as a decline in learning and cognitive ability, and a gradual loss of self-care ability. The clinical characteristics of Alzheimer's disease are insidious onset, progressive aggravation, and death due to complications within 10-20 years of onset. Alzheimer's disease accounts for 60-80% of all dementia patients and is the most common type of dementia. [0003] Regarding the pathogenesis of Alzheimer's disease, there are currently more than a dozen hypotheses in modern medicine, and the most studied are the theory of cholinergic loss, the theory of hyperphosphorylation of Tau protein, the theory of oxidative stres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A23L33/135A23L11/50A23L19/00A23L29/00A23C9/123A61K35/745A61P25/28A61P1/00C12R1/01
CPCC12N1/20A23L33/135A23L19/00A23L29/065A23C9/1234A61K35/745A61P25/28A61P1/00A23V2002/00A23V2400/519A23V2200/322A23V2200/3204
Inventor 王刚朱广素陈卫赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com